Market Place
Sourcing Support
Clearside Bio Partners with Arctic Vision for Uveitic Macular Edema
07 Nov 2024 //
GLOBENEWSWIRE
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 Jun 2024 //
GLOBENEWSWIRE
Santen Agrees to Licensing Agreements for its Pharmaceutical Products
18 Jul 2023 //
BUSINESSWIRE
Santen Announces Health Canada Approval for Cationorm
06 Oct 2022 //
BUSINESSWIRE
Santen and UBE gain FDA approval for Omlonti eye drops
28 Sep 2022 //
FIERCEPHARMA
FDA approves Santen glaucoma drug Omlonti
26 Sep 2022 //
BUSINESSWIRE
Santen launches Ducressa for post-cataract surgery
15 Aug 2022 //
PHARMATIMES
Santen’s Verkazia 0.1% Now Available for Vernal Keratoconjunctivitis
02 May 2022 //
BUSINESSWIRE
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan
07 Dec 2021 //
PRESS RELEASE
Recall of one batch of Ikervis Eye Drops, Emulsion 1mg/ml
27 Aug 2021 //
HSA
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101
10 Aug 2021 //
PRESS RELEASE
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101
10 Aug 2021 //
PRESS RELEASE
Santen, IAPB take action to implement first-ever UN General Assembly resolution
26 Jul 2021 //
BUSINESSWIRE
Santen , IAPB First Ever UN Resolution Recognizing the Link Between Eye Health
26 Jul 2021 //
BUSINESSWIRE
Verkazia for the Treatment of Severe Vernal Keratoconjunctivitis
30 Jun 2021 //
BUSINESSWIRE
Santen Receives FDA Approval for Verkazia
26 Jun 2021 //
BUSINESSWIRE
Santen launches Ducressa, a broad-spectrum, 7-day post-cataract surgery
03 Feb 2021 //
FIRSTWORD
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa®
27 Oct 2020 //
BUSINESSWIRE
Santen Announces U.S. FDA Filing Acceptance of (NDA) for Cyclosporine
26 Oct 2020 //
PRNEWSWIRE
Santen Announces U.S. FDA Filing Acceptance of NDAfor Cyclosporine
26 Oct 2020 //
PRNEWSWIRE
Santen, Orbis to tackle increasing burden of eye diseases in Asia
09 Oct 2020 //
BIOSPECTRUMASIA
Santen and Orbis International Announce Long-term Partnership
07 Oct 2020 //
PRNEWSWIRE
Santen & RVL an Osmotica Company, Enter into an Exclusive License Agreement
28 Jul 2020 //
GLOBENEWSWIRE
Santen and Singapore`s Health-tech Start-up, Plano Form a Strategic Alliance
29 Jun 2020 //
PRNASIA
Santen and Orbis International Join Forces to Train Eye Care Professionals
18 Jun 2020 //
PR NEWSWIRE
Bayer Yakuhin and Santen launch “EYLEA® Intravitreal Injection KIT 40mg/Ml
05 Jun 2020 //
EIR-PARTS
jCyte Enters into Ex-US Licensing and Commercialization Agreement jCell Therapy
08 May 2020 //
BUSINESSWIRE
Santen, Tracon discontinue development of eye drug after mid-stage trial failure
10 Mar 2020 //
SPGLOBAL
Santen EMEA announces RWD on Taptiqom
26 Feb 2020 //
PHARMATIMES
Santen partners with Verily, WHO in visual impairment drive
10 Feb 2020 //
PHARMA TIMES
Santen partners with Verily, WHO in visual impairment drive
07 Feb 2020 //
PHARMA TIMES
Verily plans digital eye care joint venture with Santen Pharma
05 Feb 2020 //
FIERCE BIOTECH
Verily plans digital eye care joint venture with Santen Pharma
04 Feb 2020 //
FIERCE BIOTECH
Oxford Biomedica, Santen ink gene therapy pact
26 Jun 2019 //
ENDPTS
SMC accepts four medicines for NHS use
11 Dec 2018 //
PHARMA TIMES
Santen Expands Research and Development Leadership Team
16 Nov 2018 //
PR NEWSWIRE
PeptiDream Announces Development Agreement with Santen Pharmaceutical
26 Sep 2018 //
BUSINESSWIRE
Zioptan (tafluprost) : Santen Pharmaceutical v. Micro Labs USA Inc.
02 Aug 2018 //
PATENT LITIGATION
Serialisation legislation could improve recall process for drugmakers - exec
13 Jun 2018 //
IN PHARMATECHNOLOGIST
Luis Iglesias heads Santen EMEA
07 Mar 2018 //
PMLIVE
Mundipharma expands partnership with Santen Pharma
29 Jan 2018 //
BIOSPECTRUM
Mixed late-stage data for Santen eye drug, but still plots FDA submission
28 Nov 2016 //
FIERCE BIOTECH
Final NICE nod for dry eye drug
15 Dec 2015 //
PHARMATIMES
Santen launches Taptiqom preservative-free fixed combination eye drops in UK
14 Jul 2015 //
PBR
Uncertain NHS future for Santen`s dry eye disease drug
24 Jun 2015 //
PHARMA TIMES
Santen`s Ikervis (Ciclosporin) Approved in Europe For Corneal Diseases
08 May 2015 //
EMA
Japan`s R-Tech Ueno buys rights on corneal defects candidate from Santen
27 Apr 2015 //
FIERCE PHARMA ASIA
